SCHEMBL1788946

SCHEMBL1788946

CCN1CCc2ccc(C(=O)OC)cc2CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.53
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 2/20 0.51
DRD2 P14416 1/20 0.49
DRD1 P21728 1/20 0.49
HDAC6 Q9UBN7 2/20 0.48
HDAC1 Q13547 1/20 0.48
ALOX12 P18054 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
XIAP P98170 1/20 0.46
BIRC2 Q13490 1/20 0.46
TP53 P04637 1/20 0.46
CHRM2 P08172 2/20 0.45
CHRM4 P08173 2/20 0.45
CHRM5 P08912 2/20 0.45
CHRM1 P11229 2/20 0.45
CHRM3 P20309 2/20 0.45
SRD5A1 P18405 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20178679 0.92 ACACB (0.59) ACACBKDM4EALDH1A1HDAC6MAPK1
SCHEMBL1959722 0.89 ACACB (0.51) ACACBHDAC6HDAC1XIAPBIRC2
SCHEMBL12608358 0.84 HDAC6 (0.50) ACACBKDM4EALDH1A1DRD2DRD1
SCHEMBL10120343 0.82 HDAC6 (0.63) DRD2DRD1HDAC6HDAC1
SCHEMBL9644030 0.82 CA1 (0.55) KDM4EALDH1A1ALOX12SMN1; SMN2HSD17B10
SCHEMBL20178659 0.82 NAMPT (0.56) ACACBKDM4EALDH1A1HDAC6ALOX12
SCHEMBL3307342 0.81 DRD1 (0.51) ACACBKDM4EALDH1A1DRD1HDAC6
SCHEMBL9949280 0.80 HDAC6 (0.45) ACACBKDM4EALDH1A1HDAC6HDAC1
SCHEMBL24192400 0.80 ACACB (0.51) ACACBKDM4EALDH1A1MAPK1HSD17B10
SCHEMBL883530 0.79 ALDH1A1 (0.61) KDM4EALDH1A1SMN1; SMN2HSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 ACACB 1604/4885KDM4E 1983/4885ALDH1A1 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.